# A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function

> **NCT07694869** · PHASE1 · RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 16 (estimated)

## Conditions studied

- Healthy Participants
- Participants With Moderate Renal Impairment

## Interventions

- **DRUG:** ammoxetine hydrochloride enteric-coated tablets

## Key facts

- **NCT ID:** NCT07694869
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-10
- **Primary completion:** 2026-10-10
- **Final completion:** 2026-11-11
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07694869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07694869, "A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07694869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*